Autres langues Surrozen, Inc.

Actions

SRZN

US86889P2083

Marché Fermé - Nasdaq Autres places de cotation 22:30:00 26/04/2024			Varia. 5j.	Varia. 1 janv.
8,98 ^USD	+4,30%		-4,52%	-4,47%

10/04	Surrozen, Inc. annonce ses résultats pour l'exercice clos le 31 décembre 2023	CI
08/04	Un initié de Surrozen a acheté des actions pour une valeur de 2 999 994 $, selon un récent dépôt auprès de la SEC	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Surrozen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	10/04
Surrozen Insider Bought Shares Worth $2,999,994, According to a Recent SEC Filing	08/04
Surrozen, Inc. announced that it has received $17.500008 million in funding from The Column Group, LLC, Ra Capital Management, Inc.	04/04
Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis	03/04
Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043	01/04
Surrozen Announces up to $192.5 Million Private Placement of Securities Priced At-the-Market Under Nasdaq Rules	01/04
Surrozen Provides Update on the Phase 1A Clinical Trial of SZN-043 in Healthy Volunteers and Patients with Cirrhosis	01/04
Surrozen, Inc. announced that it expects to receive $17.549999 million in funding	01/04
Surrozen, Inc. Appoints Charles Williams to the Concurrent Position of Chief Operating Officer	07/02
Sector Update: Health Care Stocks Softer Late Thursday Afternoon	18/01
Sector Update: Health Care Stocks Weaker Thursday Afternoon	18/01
Surrozen to Stop Inflammatory Bowel Disease Clinical Trial; Shares Fall	18/01
Surrozen Provides Corporate Update on Clinical Programs	18/01
Surrozen, Inc. Provides Corporate Update on Clinical Programs	18/01
Surrozen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	08/11
Surrozen Provides Third Quarter 2023 Financial Results	08/11
Surrozen, Inc. Expects to Initiate A Phase 1a Clinical Trials for SZN-043 and SZN-1326 in Moderate to Severe Alcoholic Hepatitis	08/11
Surrozen, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	09/08/23
Surrozen Provides Second Quarter 2023 Financial Results	09/08/23
Surrozen, Inc. Announces Management Changes	19/07/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Surrozen, Inc.

Actions

SRZN

US86889P2083

Autres langues

Filtres